{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T23:11:03Z","timestamp":1795216263377,"version":"4.10.3"},"reference-count":81,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:00:00Z","timestamp":1760572800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013920","name":"VHL Alliance","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013920","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018828","name":"Intuitive Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018828","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100030732","name":"MSD","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100030732","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Open Science"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.euros.2025.10.009","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T04:56:28Z","timestamp":1762318588000},"page":"131-141","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Genetic Testing and Counselling for Hereditary Renal Carcinoma: What Do Clinicians Need to Know?"],"prefix":"10.1016","volume":"82","author":[{"given":"Chiara","family":"Re","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Pecoraro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grant D.","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Cali\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selcuk","family":"Erdem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tugba","family":"Kalayci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zehra Oya","family":"Uyguner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Larcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Campi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Amparore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Whitworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Marandino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euros.2025.10.009_b0005","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/nrurol.2010.47","article-title":"The genetic basis of kidney cancer: a metabolic disease","volume":"7","author":"Linehan","year":"2010","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.euros.2025.10.009_b0010","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.eururo.2025.02.020","article-title":"European Association of Urology guidelines on renal cell carcinoma: the 2025 update","volume":"87","author":"Bex","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2025.10.009_b0015","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1001\/jamaoncol.2018.1986","article-title":"Prevalence of germline variants in cancer susceptibility genes in patients with advanced renal cell carcinoma","volume":"4","author":"Carlo","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.euros.2025.10.009_b0020","doi-asserted-by":"crossref","first-page":"3957","DOI":"10.1002\/cncr.33679","article-title":"Genetic risk assessment for hereditary renal cell carcinoma: clinical consensus statement","volume":"127","author":"Bratslavsky","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.euros.2025.10.009_b0025","doi-asserted-by":"crossref","first-page":"3560","DOI":"10.1200\/JCO.2018.79.2523","article-title":"Genetic predisposition to renal cell carcinoma: implications for counseling, testing, screening, and management","volume":"36","author":"Shuch","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euros.2025.10.009_b0030","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/gim.2014.147","article-title":"A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment","volume":"17","author":"Hampel","year":"2015","journal-title":"Genet Med"},{"key":"10.1016\/j.euros.2025.10.009_b0035","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/MOU.0000000000000646","article-title":"Inherited kidney cancer syndromes","volume":"29","author":"Ball","year":"2019","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.euros.2025.10.009_b0040","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.eururo.2019.06.015","article-title":"Familial kidney cancer: implications of new syndromes and molecular insights","volume":"76","author":"Carlo","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2025.10.009_b0045","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/nrneph.2013.144","article-title":"Renal cancer in von Hippel\u2013Lindau disease and related syndromes","volume":"9","author":"Bausch","year":"2013","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.euros.2025.10.009_b0050","unstructured":"European Reference Networks. von-Hippel Lindau disease (vHL). Last update: September 2023. https:\/\/www.genturis.eu\/l=eng\/Thematic-disease-groups\/Other-rare-genturis\/von-Hippel-Lindau-disease.html."},{"key":"10.1016\/j.euros.2025.10.009_b0055","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/ejhg.2010.175","article-title":"von Hippel-Lindau disease: a clinical and scientific review","volume":"19","author":"Maher","year":"2011","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.euros.2025.10.009_b0060","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(03)13643-4","article-title":"von Hippel-Lindau disease","volume":"361","author":"Lonser","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.euros.2025.10.009_b0065","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1136\/jmg.28.7.443","article-title":"von Hippel-Lindau disease: a genetic study","volume":"28","author":"Maher","year":"1991","journal-title":"J Med Genet"},{"key":"10.1016\/j.euros.2025.10.009_b0070","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.hoc.2023.04.013","article-title":"Hereditary renal cell carcinoma syndromes","volume":"37","author":"Carlo","year":"2023","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.euros.2025.10.009_b0075","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/j.gim.2022.05.006","article-title":"Frequency of truncating FLCN variants and Birt-Hogg-Dub\u00e9-associated phenotypes in a health care system population","volume":"24","author":"Savatt","year":"2022","journal-title":"Genet Med"},{"key":"10.1016\/j.euros.2025.10.009_b0080","unstructured":"European Reference Networks. Birt-Hogg-Dub\u00e9 syndrome (BHD syndrome). Last update: February 2025. https:\/\/www.genturis.eu\/l=eng\/thematic-disease-groups\/other-rare-genturis\/birt-hogg-dube-syndrome.html."},{"key":"10.1016\/j.euros.2025.10.009_b0085","first-page":"393","article-title":"Risk of renal and colonic neoplasms and spontaneous pneumothorax in the Birt-Hogg-Dub\u00e9 syndrome","volume":"11","author":"Zbar","year":"2002","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.euros.2025.10.009_b0090","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.eururo.2025.03.012","article-title":"Renal neoplasia in Birt-Hogg-Dub\u00e9 syndrome: integrated histopathologic, bulk, and single-cell transcriptomic analysis","volume":"88","author":"Gupta","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2025.10.009_b0095","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.euo.2019.11.002","article-title":"Hereditary leiomyomatosis and renal cell cancer: clinical, molecular, and screening features in a cohort of 185 affected individuals","volume":"3","author":"Forde","year":"2020","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euros.2025.10.009_b0100","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/ng849","article-title":"Germline variants in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer","volume":"30","author":"Tomlinson","year":"2002","journal-title":"Nat Genet"},{"key":"10.1016\/j.euros.2025.10.009_b0105","unstructured":"European Reference Networks. Hereditary leiomyomatosis and renal cell cancer (HLRCC). Last update: April 2023. https:\/\/www.genturis.eu\/l=eng\/thematic-disease-groups\/other-rare-genturis\/hereditary-leiomyomatosis-and-renal-cell-cancer.html."},{"key":"10.1016\/j.euros.2025.10.009_b0110","doi-asserted-by":"crossref","first-page":"e113","DOI":"10.1016\/j.eururo.2022.12.020","article-title":"Improving systemic therapy for fumarate hydratase-deficient renal cell carcinoma","volume":"83","author":"Carlo","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2025.10.009_b0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2024.100561","article-title":"Comparison of primary and metastatic fumarate hydratase-deficient renal cell carcinomas documents morphologic divergence and potential diagnostic pitfall with peritoneal mesothelioma","volume":"37","author":"Cali\u00f2","year":"2024","journal-title":"Mod Pathol"},{"key":"10.1016\/j.euros.2025.10.009_b0120","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1097\/PAS.0000000000001476","article-title":"Report From the International Society of Urological Pathology (ISUP) consultation conference on molecular pathology of urogenital cancers: III: molecular pathology of kidney cancer","volume":"44","author":"Williamson","year":"2020","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.euros.2025.10.009_b0125","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1093\/ndt\/gfaf032","article-title":"The impact of the new WHO classification of renal cell carcinoma on the diagnosis of hereditary leiomyomatosis and renal cell carcinoma","volume":"40","author":"Degenhardt","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.euros.2025.10.009_b0130","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.humpath.2022.12.013","article-title":"Characterization of protein S-(2-succino)-cysteine (2SC) succination as a biomarker for fumarate hydratase-deficient renal cell carcinoma","volume":"134","author":"Mannan","year":"2023","journal-title":"Hum Pathol"},{"key":"10.1016\/j.euros.2025.10.009_b0135","unstructured":"European Reference Networks. Hereditary papillary renal cell carcinoma (HPRC). Last update: April 2023. https:\/\/www.genturis.eu\/l=eng\/thematic-disease-groups\/other-rare-genturis\/hereditary-papillary-renal-cell-carcinoma.html."},{"key":"10.1016\/j.euros.2025.10.009_b0140","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1097\/01.ju.0000052373.36963.12","article-title":"Familial papillary renal cell tumors and subsequent cancers: a nationwide epidemiological study from Sweden","volume":"169","author":"Czene","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.euros.2025.10.009_b0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2022.105389","article-title":"Defining the origin, evolution, and immune composition of SDH-deficient renal cell carcinoma","volume":"25","author":"Neves","year":"2022","journal-title":"iScience"},{"key":"10.1016\/j.euros.2025.10.009_b0150","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/nrc1013","article-title":"A role for mitochondrial enzymes in inherited neoplasia and beyond","volume":"3","author":"Eng","year":"2003","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.euros.2025.10.009_b0155","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1136\/jmedgenet-2017-105127","article-title":"Tumour risks and genotype-phenotype correlations associated with germline variants in succinate dehydrogenase subunit genes SDHB","volume":"55","author":"Andrews","year":"2018","journal-title":"SDHC and SDHD. J Med Genet"},{"key":"10.1016\/j.euros.2025.10.009_b0160","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.eururo.2016.02.029","article-title":"The 2016 WHO classification of tumours of the urinary system and male genital organs\u2014part A: renal, penile, and testicular tumours","volume":"70","author":"Moch","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2025.10.009_b0165","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1097\/PAS.0000000000000292","article-title":"Succinate dehydrogenase (SDH)-deficient renal carcinoma: a morphologically distinct entity: a clinicopathologic series of 36 tumors from 27 patients","volume":"38","author":"Gill","year":"2014","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.euros.2025.10.009_b0170","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMra055323","article-title":"The tuberous sclerosis complex","volume":"355","author":"Crino","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euros.2025.10.009_b0175","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.3390\/genes12101585","article-title":"Renal cell carcinoma in tuberous sclerosis complex","volume":"12","author":"Henske","year":"2021","journal-title":"Genes"},{"key":"10.1016\/j.euros.2025.10.009_b0180","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1007\/s00467-020-04775-1","article-title":"Renal tumors in tuberous sclerosis complex","volume":"36","author":"Trnka","year":"2021","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.euros.2025.10.009_b0185","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.pathol.2020.08.008","article-title":"Angiomyolipoma of the kidney: from simple hamartoma to complex tumour","volume":"53","author":"Cali\u00f2","year":"2021","journal-title":"Pathology"},{"key":"10.1016\/j.euros.2025.10.009_b0190","doi-asserted-by":"crossref","first-page":"307","DOI":"10.32074\/1591-951X-335","article-title":"Epithelioid angiomyolipoma: a pathological entity discovered in Verona with the endorsement of Doctor Rosai","volume":"113","author":"Cali\u00f2","year":"2021","journal-title":"Pathologica"},{"key":"10.1016\/j.euros.2025.10.009_b0195","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/PAS.0b013e318206f2a9","article-title":"Pure epithelioid PEComas (so-called epithelioid angiomyolipoma) of the kidney: a clinicopathologic study of 41 cases: detailed assessment of morphology and risk stratification","volume":"35","author":"Nese","year":"2011","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.euros.2025.10.009_b0200","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1097\/PAS.0b013e3181d90370","article-title":"Renal epithelioid angiomyolipoma with atypia: a series of 40 cases with emphasis on clinicopathologic prognostic indicators of malignancy","volume":"34","author":"Brimo","year":"2010","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.euros.2025.10.009_b0205","doi-asserted-by":"crossref","first-page":"319","DOI":"10.5489\/cuaj.1496","article-title":"Canadian guideline on genetic screening for hereditary renal cell cancers","volume":"7","author":"Reaume","year":"2013","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.euros.2025.10.009_b0210","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/JU.0000000000001911","article-title":"Renal mass and localized renal cancer: evaluation, management, and follow-up: AUA guideline: part I","volume":"206","author":"Campbell","year":"2021","journal-title":"J Urol"},{"key":"10.1016\/j.euros.2025.10.009_b0215","article-title":"NCCN guidelines insights: kidney cancer, version 3.2025. Plymouth Meeting, PA: National Comprehensive Cancer","author":"Motzer","year":"2025","journal-title":"Network"},{"key":"10.1016\/j.euros.2025.10.009_b0220","unstructured":"National Health Service. National genomic test directory. Testing criteria for rare and inherited disease. London, UK: NHS; 2021. https:\/\/www.england.nhs.uk\/wp-content\/uploads\/2018\/08\/rare-and-inherited-disease-eligibility-criteria-v2.pdf (last access May 2025)."},{"key":"10.1016\/j.euros.2025.10.009_b0225","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1007\/s00345-018-2288-5","article-title":"Hereditary renal cell carcinoma syndromes: diagnosis, surveillance and management","volume":"36","author":"Maher","year":"2018","journal-title":"World J Urol"},{"key":"10.1016\/j.euros.2025.10.009_b0230","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.1093\/hmg\/ddac089","article-title":"Frequency of pathogenic germline variants in cancer susceptibility genes in 1336 renal cell carcinoma cases","volume":"31","author":"Yngvadottir","year":"2022","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.euros.2025.10.009_b0235","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1200\/JCO.2013.50.8192","article-title":"Defining early-onset kidney cancer: implications for germline and somatic mutation testing and clinical management","volume":"32","author":"Shuch","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euros.2025.10.009_b0240","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.euo.2021.09.005","article-title":"Germline variants identified in patients with early-onset renal cell carcinoma referred for germline genetic testing","volume":"4","author":"Truong","year":"2021","journal-title":"Eur Urol Oncol."},{"key":"10.1016\/j.euros.2025.10.009_b0245","first-page":"274","article-title":"Clinical predictors of a positive test result in patients undergoing genetic evaluation for a hereditary kidney cancer syndrome","volume":"14","author":"Kokorovic","year":"2020","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.euros.2025.10.009_b0250","doi-asserted-by":"crossref","first-page":"17","DOI":"10.15586\/jkcvhl.v10i3.242","article-title":"Hereditary renal cell carcinoma: is age an independent criterion for genetic testing? A large cohort from a Latin America referral center","volume":"10","author":"Carminatti","year":"2023","journal-title":"J Kidney Cancer VHL"},{"key":"10.1016\/j.euros.2025.10.009_b0255","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1001\/jama.2017.11137","article-title":"Mutation detection in patients with advanced cancer by universal sequencing of cancer-related genes in tumor and normal DNA vs guideline-based germline testing","volume":"318","author":"Mandelker","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.euros.2025.10.009_b0260","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.euf.2019.09.005","article-title":"Genetic testing in kidney cancer patients: who, when, and how?","volume":"5","author":"Lui","year":"2019","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euros.2025.10.009_b0265","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1093\/eurpub\/ckae093","article-title":"Genetic counselling legislation and practice in cancer in EU member states","volume":"34","author":"McCrary","year":"2024","journal-title":"Eur J Public Health"},{"key":"10.1016\/j.euros.2025.10.009_b0270","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1038\/s41431-022-01189-5","article-title":"The role of the genetic counsellor in the multidisciplinary team: the perception of geneticists in Europe","volume":"30","author":"Catapano","year":"2022","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.euros.2025.10.009_b0275","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/mgg3.123","article-title":"Genetic counselors and genomic counseling in the United Kingdom","volume":"3","author":"Middleton","year":"2015","journal-title":"Mol Genet Genomic Med"},{"key":"10.1016\/j.euros.2025.10.009_b0280","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/s41431-018-0252-x","article-title":"The global state of the genetic counseling profession","volume":"27","author":"Abacan","year":"2019","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.euros.2025.10.009_b0285","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.3390\/cancers14041059","article-title":"The feasibility of implementing mainstream germline genetic testing in routine cancer care\u2014a systematic review","volume":"14","author":"Bokkers","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.euros.2025.10.009_b0290","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41431-022-01212-9","article-title":"The genetic counsellor role in the United Kingdom: position on behalf of the Association of Genetic Nurses and Counsellors(AGNC), endorsed by the Genetic Counsellor Registration Board (GCRB) and Academy for Healthcare Science (AHCS)","volume":"31","author":"Middleton","year":"2023","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.euros.2025.10.009_b0295","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s10897-005-9014-3","article-title":"A new definition of genetic counseling: national society of genetic counselors\u2019 task force report","volume":"15","author":"Resta","year":"2006","journal-title":"J Genet Couns"},{"key":"10.1016\/j.euros.2025.10.009_b0300","doi-asserted-by":"crossref","first-page":"3660","DOI":"10.1200\/JCO.2015.63.0996","article-title":"American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility","volume":"33","author":"Robson","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euros.2025.10.009_b0305","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American college of medical genetics and genomics and the association for molecular pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med"},{"key":"10.1016\/j.euros.2025.10.009_b0310","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/MOU.0000000000000950","article-title":"Von Hippel-Lindau disease-associated renal cell carcinoma: a call to action","volume":"32","author":"Larcher","year":"2022","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.euros.2025.10.009_b0315","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1002\/cncr.34896","article-title":"Guidelines for surveillance of patients with von Hippel-Lindau disease: consensus statement of the International VHL surveillance guidelines consortium and VHL alliance","volume":"129","author":"Daniels","year":"2023","journal-title":"Cancer"},{"key":"10.1016\/j.euros.2025.10.009_b0320","article-title":"von Hippel-Lindau disease: updated guideline for diagnosis and surveillance","volume":"65","author":"Binderup","year":"2022","journal-title":"Eur J Med Genet"},{"key":"10.1016\/j.euros.2025.10.009_b0325","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1007\/s00345-020-03574-5","article-title":"Clinical, surgical, pathological and follow-up features of kidney cancer patients with Von Hippel-Lindau syndrome: novel insights from a large consortium","volume":"39","author":"Capitanio","year":"2021","journal-title":"World J Urol"},{"key":"10.1016\/j.euros.2025.10.009_b0330","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1056\/NEJMoa2103425","article-title":"Belzutifan for renal cell carcinoma in von Hippel-Lindau disease","volume":"385","author":"Jonasch","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euros.2025.10.009_b0335","unstructured":"US Food and Drug Administration. FDA approves belzutifan for advanced renal cell carcinoma. Silver Spring, MD: FDA; 2023. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-belzutifan-advanced-renal-cell-carcinoma."},{"key":"10.1016\/j.euros.2025.10.009_b0340","unstructured":"European Medicines Agency. Welireg (belzutifan). Amsterdam, The Netherlands: EMA; 2024. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/welireg."},{"key":"10.1016\/j.euros.2025.10.009_b0345","first-page":"205","article-title":"Treatment strategies for hereditary kidney cancer: current recommendations and updates","volume":"34","author":"Singh","year":"2022","journal-title":"Discov Med"},{"key":"10.1016\/j.euros.2025.10.009_b0350","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1200\/JCO.2012.43.3383","article-title":"Phase II and biomarker study of the dual MET\/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma","volume":"31","author":"Choueiri","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euros.2025.10.009_b0355","unstructured":"PDQ Cancer Genetics Editorial Board. Cancer genetics risk assessment and counseling (PDQ\u00ae): health professional version. In: PDQ cancer information summaries. Bethesda, MD: National Cancer Institute; 2002\u2013. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK65817\/."},{"key":"10.1016\/j.euros.2025.10.009_b0360","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/S1470-2045(09)70188-3","article-title":"Birt-Hogg-Dub\u00e9 syndrome: diagnosis and management","volume":"10","author":"Menko","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euros.2025.10.009_b0365","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1200\/JCO.21.01944","article-title":"Phase II trial of cabozantinib plus nivolumab in patients with non-clear-cell renal cell carcinoma and genomic correlates","volume":"40","author":"Lee","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euros.2025.10.009_b0370","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.eururo.2022.05.029","article-title":"Genomic profiling and response to immune checkpoint inhibition plus tyrosine kinase inhibition in FH-deficient renal cell carcinoma","volume":"83","author":"Xu","year":"2023","journal-title":"Eur Urol"},{"issue":"15 Suppl","key":"10.1016\/j.euros.2025.10.009_b0375","doi-asserted-by":"crossref","first-page":"5004","DOI":"10.1200\/JCO.2020.38.15_suppl.5004","article-title":"Results from a phase II study of bevacizumab and erlotinib in subjects with advanced hereditary leiomyomatosis and renal cell cancer (HLRCC) or sporadic papillary renal cell cancer","volume":"38","author":"Srinivasan","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euros.2025.10.009_b0380","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0140-6736(12)61767-X","article-title":"Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"381","author":"Bissler","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.euros.2025.10.009_b0385","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1056\/NEJMoa1001671","article-title":"Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis","volume":"363","author":"Krueger","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euros.2025.10.009_b0390","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1212\/WNL.0000000000003400","article-title":"Long-term treatment of epilepsy with everolimus in tuberous sclerosis","volume":"87","author":"Krueger","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.euros.2025.10.009_b0395","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1002\/mc.23164","article-title":"Comprehensive analysis of somatic copy number alterations in clear cell renal cell carcinoma","volume":"59","author":"Tsuyukubo","year":"2020","journal-title":"Mol Carcinog"},{"key":"10.1016\/j.euros.2025.10.009_b0400","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/nature10539","article-title":"A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma","volume":"480","author":"Bertolotto","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.euros.2025.10.009_b0405","doi-asserted-by":"crossref","first-page":"7494","DOI":"10.1038\/s41467-022-34460-w","article-title":"Proteogenomic characterization of MiT family translocation renal cell carcinoma","volume":"13","author":"Qu","year":"2022","journal-title":"Nat Commun"}],"container-title":["European Urology Open Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666168325014399?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666168325014399?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T08:04:56Z","timestamp":1766131496000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666168325014399"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":81,"alternative-id":["S2666168325014399"],"URL":"https:\/\/doi.org\/10.1016\/j.euros.2025.10.009","relation":{},"ISSN":["2666-1683"],"issn-type":[{"value":"2666-1683","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genetic Testing and Counselling for Hereditary Renal Carcinoma: What Do Clinicians Need to Know?","name":"articletitle","label":"Article Title"},{"value":"European Urology Open Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euros.2025.10.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}